Medigene (MDGEF) Stock Price, News & Analysis

Company Overview

Medigene AG is a Germany-based clinical-stage biopharmaceutical company focused on developing T cell-based immunotherapies for cancer. The company’s core expertise lies in the identification, optimization and clinical development of T cell receptors (TCRs) that target tumor-associated antigens. Through its proprietary platforms, Medigene generates TCR libraries and refines them for affinity, specificity and safety with the goal of delivering adoptive cell therapies capable of recognizing and eradicating malignant cells.

The company’s product pipeline includes personalized and off-the-shelf TCR-T cell candidates directed against hematologic and solid tumor indications. Medigene’s lead programs are in early to mid-stage clinical trials, where its engineered T cells are evaluated both as monotherapies and in combination with checkpoint inhibitors. In addition to TCR-T approaches, Medigene leverages dendritic cell vaccine technology to prime anti-tumor immunity and is exploring partnerships to expand its therapeutic modalities.

Founded in 1994 and headquartered in Martinsried, near Munich, Medigene serves global markets through its European operations and an over-the-counter listing in the United States under the symbol MDGEF. The company’s management team comprises experienced life science executives and scientific leaders with backgrounds in cellular immunology, clinical development and regulatory affairs. Medigene continues to advance its immuno-oncology programs with the aim of delivering novel therapies to patients with high-unmet-need cancers.

Key Stats

• Today's Range: $0.10 to $0.10
• 50-Day Range: $0.10 to $0.10
• 52-Week Range: $0.10 to $1.30
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MDGEF Stock Analysis - Frequently Asked Questions

How have MDGEF shares performed this year?

Medigene's stock was trading at $1.2950 at the beginning of 2025. Since then, MDGEF stock has decreased by 92.3% and is now trading at $0.10.

When did Medigene's stock split?

Shares of Medigene reverse split on the morning of Saturday, January 1st 2000.A 1-2 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

How do I buy shares of Medigene?

Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MDGEF
• CIK: N/A
• Web: www.medigene.com
• Phone: (989) 200-0330
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A